Can patient input be meaningful in research?

What is it about?

"Can We" and "Should We"? These are the two essential questions in the evolution of drug development. Traditionally, concentration and focus was primarily on the science ("Can We?). The process we describe in this paper addresses the "Should We" - what is the identified patient need and how can it be integrated into the drug development and decision-making process. It brings the patient into the research and development continuum and identifies asset characteristics deemed important to both patients and clinicians. The combination of science with the patient and clinician perspective will be a critical component in the development of drugs that are meaningful to patients.

Featured Image

Why is it important?

Integrating the patient perspective with sound science in early research and development will allow for better decision-making regarding portfolio prioritization and investment choices. Most importantly, if done consistently and integrated into the decision-making processes of organizations it will bring to market medicines that are more aligned with the needs of our patients.